NBIX241115P85000
- 0.00
- 0.000.00%
Neurocrine Biosciences Newsroom
US Manufacturing Index Rises To 43, Highest Since 2020
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $160
Neurocrine Biosciences Positioned for Growth Amid AbbVie's Setback in Muscarinic Program
Neurocrine Biosciences To Present At UBS Global Healthcare Conference; Webcast At 4:15 PM ET
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie's Disappointing Schizophrenia Drug Trial Bodes Well for Rival Bristol Myers, Analysts Say
Jefferies Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $158
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192
Neurocrine Biosciences Analyst Ratings
Evercore Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $175
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality
Neurocrine (NBIX) Gets a Buy From J.P. Morgan
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
Neurocrine Biosciences: Balancing Strategic Priorities With Regulatory Challenges – Analyst Maintains Hold Rating
Neurocrine Biosciences Unveils KINECT-HD Data Demonstrating Consistent Efficacy Of INGREZZA In Huntington's Disease Chorea Across 19 Subgroups, Showing Positive Impact On Emotional Health
Express News | Neurocrine Biosciences Inc : JP Morgan Raises Target Price to $184 From $181
Neurocrine Biosciences Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA (Valbenazine) Capsules
CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $167
Neurocrine Biosciences to Participate at Investor Conferences in November
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $166